Imunon
Yahoo Finance • last year
IMUNON’s VP of R&D to Present at the Vaccines Summit-2023
Dr. Jean Boyer to highlight updated data showing the advantages of IMUNON’s PlaCCine modality and its applicability to multiple pathogens LAWRENCEVILLE, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-sta... Full story
Yahoo Finance • last year
IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update
Advances Non-Viral DNA-Mediated Cancer Immunotherapy and Next-Generation Vaccine Programs, with More Potent and Durable Immunity, with Multiple Near-Term Milestones Conference Call Begins Today at 10:00 a.m. ET LAWRENCEVILLE, N.J., Nov.... Full story
Yahoo Finance • last year
IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023
LAWRENCEVILLE, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will... Full story
Yahoo Finance • last year
IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress
Highlights advantages of IMUNON’s PlaCCine modality over current commercial vaccines LAWRENCEVILLE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company focused on harnessing the po... Full story
Yahoo Finance • last year
IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations
“A Tale of Two Pandemics: Lessons From the 1889 & 2019 Pandemics” presented by the Foreign Policy Association LAWRENCEVILLE, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company foc... Full story
Yahoo Finance • last year
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
The MRD trial will evaluate the effect of this treatment combination on minimal residual disease. LAWRENCEVILLE, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on d... Full story
Yahoo Finance • last year
IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board
Renowned Daner-Farber Cancer Institute researcher will advise on the development of IMUNON’s FixPlas™ and Indiplas™ modalities in immuno-oncology. LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a cli... Full story
Yahoo Finance • last year
IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer
Intent-to-treat population shows 9-month OS improvement over control arm Subgroup of patients treated with IMNN-001 + PARPi shows meaningful PFS and OS trend compared with control arm Continued follow-up is indicated to confirm initial o... Full story
Yahoo Finance • last year
IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies
Provides a look at the new manufacturing facility in Huntsville, Alabama Introduced as part of IMUNON's newly relaunched website LAWRENCEVILLE, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biot... Full story
Yahoo Finance • last year
IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET
Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq:IMNN), a clinical-stage biotechnology company foc... Full story
Yahoo Finance • last year
IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET
Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq:IMNN), a clinical-stage b... Full story
Yahoo Finance • last year
IMUNON to Participate in the H.C. Wainwright Global Investment Conference
LAWRENCEVILLE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being... Full story
Yahoo Finance • last year
IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus
CRADA will evaluate the immunogenicity and efficacy of two DNA-based Lassa virus vaccine candidates in animal models LAWRENCEVILLE, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology comp... Full story
Yahoo Finance • last year
IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla
Renowned scientist will advise on the development of IMUNON’s FixPlas and IndiPlas modalities in immuno-oncology LAWRENCEVILLE, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development compa... Full story
Yahoo Finance • last year
IMUNON Unveils New Manufacturing Capabilities at Huntsville’s HudsonAlpha Biotech Campus
Production of cGMP Clinical Materials Supports R&D Efficiencies and Lowers Costsfor Infectious Disease and Cancer Vaccines, and Non-viral DNA-based Immuno-Oncology Therapies HUNTSVILLE, Ala., June 27, 2023 (GLOBE NEWSWIRE) -- IMUNON, In... Full story
Yahoo Finance • last year
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
LAWRENCEVILLE, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committe... Full story
Yahoo Finance • 2 years ago
IMUNON CEO to Discuss Company’s Novel Non-viral DNA Therapy Option at the Mass General Brigham World Medical Innovation Forum 2023
Dr. Corinne Le Goff will highlight thebreakthrough potential of IMNN-001 for the treatment of ovarian cancer during a panel discussion LAWRENCEVILLE, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc.(NASDAQ: IMNN), a clinical-stage d... Full story
Yahoo Finance • 2 years ago
IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update
Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., May 11, 2023 (GLOBE NE... Full story
Yahoo Finance • 2 years ago
IMUNON to Hold First Quarter 2023 Financial Results and Business Update Conference Call on Thursday, May 11, 2023
LAWRENCEVILLE, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will h... Full story
Yahoo Finance • 2 years ago
IMUNON Presents Poster at the American Association for Cancer Research Annual Meeting Demonstrating Preclinical Immune Response of IMNN-001
Findings from a mouse model of peritoneally disseminated ovarian cancer suggest biweekly dosing regimen for further evaluation in human clinical studies LAWRENCEVILLE, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN)... Full story
